Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
19 Dicembre 2023
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
18 Dicembre 2023
Restore to Impact | Award Ceremony
14 Dicembre 2023
Chiesi explores the impact of climate change on people living with respiratory conditions in the series “The Climate and Us”
05 Dicembre 2023
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
20 Novembre 2023
Chiesi Group Partnership Day 2023
16 Novembre 2023
Chiesi Global Rare Diseases Releases Report on the Burden of Care for Rare Diseases and Its Economic Impact on European Citizens
30 Ottobre 2023
Chiesi Foundation’s NEST Partners Meeting in Sub-Saharan Africa
27 Ottobre 2023
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
01 Settembre 2023
Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health to Overall Well-Being, New Report Warns
